{
  "ticker": "CHM",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02972143",
  "id": "02972143",
  "pages": 8,
  "price_sensitive": false,
  "date": "20250724",
  "time": "0839",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250724/pdf/06m2vy09hjl25d.pdf",
  "summary": "### Capital Raising Summary:  \n- **Type**: Placement (+ attaching options)  \n- **Total Capital Raised**: AUD 5.94M (1,485,700,000 shares @ AUD 0.004 each)  \n- **Key Dates**:  \n  - Shareholder approval received: 23 July 2025  \n  - Issue date: 25 July 2025  \n\n### Additional Securities Issued:  \n1. **Options**:  \n   - 1,650,000,000 options (CHMOD) expiring 31 Mar 2026, exercise price AUD 0.004.  \n   - 25,000,000 advisor options (CHMOE) expiring 31 Jul 2028, exercise price AUD 0.008.  \n   - 1,650,000,000 contingent options (CHMOF) expiring 31 Aug 2026, exercise price AUD 0.005.  \n\n### Use of Proceeds**:  \n- Funding CHM CDH17 CAR-T and CORE-NK clinical trials.  \n- General working capital and capital raising costs.  \n\n### Fees**:  \n- 6% brokerage fee to lead managers (PAC Partners & Taylor Collison).  \n- 25M options issued to advisors (3-year term, AUD 0.008 exercise price).  \n\n**Note**: Terms refer to 20 May 2025 announcement (\"$6.6M Placement\").",
  "usage": {
    "prompt_tokens": 3284,
    "completion_tokens": 295,
    "total_tokens": 3579,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-23T22:51:04.201897"
}